Proinflammatory Mediators and Genetic Background in Oncogene Mediated Tumor Progression

Journal of Immunology

Volumn 172, Issue 7, 2004, Pages 4059-4067

  Russell, John P ^a   Engiles, Julie B ^b   Rothstein, Jay L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN RP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME SYNTHESIS; GENE FUNCTION; HASHIMOTO DISEASE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID CARCINOMA; TUMOR GROWTH;

EID: 1642320337     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.7.4059     Document Type: Article

References (54)

1. Balkwill, F., and A. Mantovani. 2001. Inflammation and cancer: back to Virchow? Lancet 357:539.
2. Mantovani, A., B. Bottazzi, F. Colotta, S. Sozzani, and L. Ruco. 1992. The origin and function of tumor-associated macrophages. Immunol. Today 13:265.
3. Hunter, T. 1997. Oncoprotein networks. Cell 88:333.
4. Portella, G., D. Vitagliano, C. Borselli, R. M. Melillo, D. Salvatore, J. L. Rothstein, G. Vecchio, A. Fusco, and M. Santoro. 1999. Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. Oncol. Res. 11:421.
5. Buckwalter, T. L., A. Venkateswaran, M. Lavender, K. M. La Perle, J. Y. Cho, M. L. Robinson, and S. M. Jhiang. 2002. The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation. Oncogene 21:8166.
6. Durick, K., V. J. Yao, M. G. Borrello, I. Bongarzone, M. A. Pierotti, and S. S. Taylor. 1995. Tyrosines outside the kinase core and dimerization are required for the mitogenic activity of RET/ptc2. J. Biol. Chem. 270:24642.
7. Borrello, M. G., L. Alberti, E. Arighi, I. Bongarzone, C. Battistini, A. Bardelli, B. Pasini, C. Piutti, M. G. Rizzetti, P. Mondellini, M. T. Radice, and M. A. Pierotti. 1996. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cγ. Mol. Cell. Biol. 16:2151.
8. Takahashi, M. 2001. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 12:361.
9. Manie, S., M. Santoro, A. Fusco, and M. Billaud. 2001. The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet. 17:580.
10. Hayashi, H., M. Ichihara, T. Iwashita, H. Murakami, Y. Shimono, K. Kawai, K. Kurokawa, Y. Murakumo, T. Imai, H. Funahashi, et al. 2000. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19:4469.
11. Karin, M., and A. Lin. 2002. NF-κB at the crossroads of life and death. Nat. Immunol. 3:221.
12. Russell, J. P., S. Shinohara, R. M. Melillo, M. D. Castellone, M. Santoro, and J. L. Rothstein. 2003. Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. Oncogene 22:4569.
13. Knauf, J. A., H. Kuroda, S. Basu, and J. A. Fagin. 2003. RET/PTC-induced dedifferentiation of thyroid cells is mediated throught Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 22:4406.
14. Yoshida, A., T. Asaga, C. Masuzawa, S. Kawahara, S. Yanoma, M. Harada, and T. Okamoto. 1994. Production of cytokines by thyroid carcinoma cell lines. J. Surg. Oncol. 55:104.
15. Aust, G., and W. A. Scherbaum. 1996. Expression of cytokines in the thyroid: thyrocytes as potential cytokine producers. Exp. Clin. Endocrinol. Diabetes 104:64.
16. Rasmussen, A. K. 2000. Cytokine actions on the thyroid gland. Dan. Med. Bull. 47:94.
17. Stassi, G., M. Todaro, M. Zerilli, L. Ricci-Vitiani, D. Di Liberto, M. Patti, A. Florena, F. Di Gaudio, G. Di Gesu, and R. De Maria. 2003. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res. 63:6784.
18. Rasmussen, A. K., K. Bendtzen, and U. Feldt-Rasmussen. 2000. Thyrocyte-interleukin-1 interactions. Exp. Clin. Endocrinol. Diabetes 108:67.
19. Deuss, U., M. Buscema, H. Schumacher, and W. Winkelmann. 1992. In vitro effects of tumor necrosis factor-α on human thyroid follicular cells. Acta Endocrinol. 127:220.
20. Zeki, K., Y. Nakano, N. Inokuchi, K. Watanabe, I. Morimoto, U. Yamashita, and S. Eto. 1993. Autocrine stimulation of interleukin-1 in the growth of human thyroid carcinoma cell line NIM 1. J. Clin. Endocrinol. Metab. 76:127.
21. Basolo, F., R. Giannini, C. Monaco, R. M. Melillo, F. Carlomagno, M. Pancrazi, G. Salvatore, G. Chiappetta, F. Pacini, R. Elisei, et al. 2002. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am. J. Pathol. 160:247.
22. Powell, D. J., Jr., J. Russell, K. Nibu, G. Li, E. Rhee, M. Liao, M. Goldstein, W. M. Keane, M. Santoro, A. Fusco, and J. L. Rothstein. 1998. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res. 58:5523.
23. Scarpino, S., A. Stoppacciaro, F. Ballerini, M. Marchesi, M. Prat, M. C. Stella, S. Sozzani, P. Allavena, A. Mantovani, and L. P. Ruco. 2000. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am. J. Pathol. 156:831.
24. Yoshida, M., H. Matsuzaki, K. Sakata, M. Takeya, K. Kato, S. Mizushima, M. Kawakita, and K. Takatsuki. 1992. Neutrophil chemotactic factors produced by a cell line from thyroid carcinoma. Cancer Res. 52:464.
25. Tohyama, K., Y. Yoshida, K. Ohashi, E. Sano, H. Kobayashi, K. Endo, M. Naruto, and T. Nakamura. 1992. Production of multiple growth factors by a newly established human thyroid carcinoma cell line. Jpn. J. Cancer Res. 83:153.
26. Russell, J. P., D. J. Powell, M. Cunnane, A. Greco, G. Portella, M. Santoro, A. Fusco. and J. L. Rothstein. 2000. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene 19:5729.
27. -/-) mice. Oncogene 20:3235.
28. Rothstein, J. L., D. Johnson, J. Jessee, J. Skowronski, J. A. DeLoia, D. Solter, and B. B. Knowles. 1993. Construction of primary and subtracted cDNA libraries from early embryos. Methods Enzymol. 225:587.
29. Cometta, A. J., J. P. Russell, M. Cunnane, W. M. Keane, and J. L. Rothstein. 2002. Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope 112:238.
30. Oka, Y., T. Kobayashi, S. Fujita, N. Matsuura, S. Okamoto, H. Asakawa, A. Murata, and T. Mori. 1993. Establishment of a human anaplastic thyroid cancer cell line secreting granulocyte colony-stimulating factor in response to cytokines. In Vitro Cell Dev. Biol. Anim. 29A:537.
31. Enomoto, T., H. Sugawa, D. Inoue, M. Miyamoto, S. Kosugi, T. Takahashi, N. Kitamura, I. Yamamoto, J. Konishi, T. Mori, et al. 1990. Establishment of a human undifferentiated thyroid cancer cell line producing several growth factors and cytokines. Cancer 65:1971.
32. Santoro, M., G. Chiappetta, A. Cerrato, D. Salvatore, L. Zhang, G. Manzo, A. Picone, G. Portella, G. Santelli, G. Vecchio, and A. Fusco. 1996. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 12:1821.
33. Jhiang, S. M., J. E. Sagartz, Q. Tong, J. Parker-Thomburg, C. C. Capen, J. Y. Cho, S. Xing, and C. Ledent. 1996. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137:375.
34. Ajuebor, M. N., R. J. Flower, R. Hannon, M. Christie, K. Bowers, A. Verity, and M. Perretti. 1998. Endogenous monocyte chemoattractant protein-1 recruits monocytes in the zymosan peritonitis model. J. Leukocyte Biol. 63:108.
35. Mantovani, A. 1994. Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab. Invest. 71:5.
36. Nicolson, G. L. 1993. Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp. Cell Res. 204:171.
37. Seung, L. P., S. K. Seung, and H. Schreiber. 1995. Antigenic cancer cells that escape immune destruction are stimulated by host cells. Cancer Res. 55:5094.
38. Seung, L. P., D. A. Rowley, P. Dubey, and H. Schreiber. 1995. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc. Natl. Acad. Sci. USA 92:6254.
39. Pekarek, L. A., B. A. Starr, A. Y. Toledano, and H. Schreiber. 1995. Inhibition of tumor growth by elimination of granulocytes. J. Exp. Med. 181:435.
40. Prehn, R. T. 1977. Immunostimulation of the lymphodependent phase of neoplastic growth. J. Natl. Cancer Inst. 59:1043.
41. Smith, P. C., A. Hobisch, D. L. Lin, Z. Culig, and E. T. Keller. 2001. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 12:33.
42. Angelo, L. S., M. Talpaz, and R. Kurzrock. 2002. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res. 62:932.
43. Neumark, E., M. A. Cohn, E. Lukanidin, I. P. Witz, and A. Ben-Baruch. 2002. Possible co-regulation of genes associated with enhanced progression of mammary adenocarcinomas. Immunol. Lett. 82:111.
44. Sasaki, A., S. Ishiuchi, T. Kanda, M. Hasegawa, and Y. Nakazato. 2001. Analysis of interleukin-6 gene expression in primary human gliomas, glioblastoma xenografts, and glioblastoma cell lines. Brain Tumor Pathol. 18:13.
45. Hida, T., Y. Yatabe, H. Achiwa, H. Muramatsu, K. Kozaki, S. Nakamura, M. Ogawa, T. Mitsudomi, T. Sugiura, and T. Takahashi. 1998. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58:3761.
46. Ristimaki, A., N. Honkanen, H. Jankala, P. Sipponen, and M. Harkonen. 1997. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57:1276.
47. Eberhart, C. E., R. J. Coffey, A. Radhika, F. M. Giardiello, S. Ferrenbach, and R. N. DuBois. 1994. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183.
48. Chan, G., J. O. Boyle, E. K. Yang, F. Zhang, P. G. Sacks, J. P. Shah, D. Edelstein, R. A. Soslow, A. T. Koki, B. M. Woerner, et al. 1999. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59:991.
49. Nose, F., T. Ichikawa, M. Fujiwara, and I. Okayasu. 2002. Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors; significant correlation with inducible nitric oxide synthase. Am. J. Clin. Pathol. 117:546.
50. Powell, D. J., Jr., L. C. Eisenlohr, and J. L. Rothstein. 2003. A thyroid tumor-specific antigen formed by the fusion of two self-proteins. J. Immunol. 170:861.
51. Wynford-Thomas, D. 1997. Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms. Horm. Res. 47:145.
52. Cho, H. Y., A. E. Jedlicka, S. P. Reddy, T. W. Kensler, M. Yamamoto, L. Y. Zhang, and S. R. Kleeberger. 2002. Role of NRF2 in protection against hyperoxic lung injury in mice. Am. J. Respir. Cell Mol. Biol. 26:175.
53. Lin, E. Y., A. V. Nguyen, R. G. Russell, and J. W. Pollard. 2001. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193:727.
54. Conover, W. 1980. Practical Nonparametric Statistics. Wiley, New York.